Temozolomide and capecitabine regimen as first-line treatment in advanced gastroenteropancreatic neuroendocrine tumors at a Latin American reference center

Table 2 Systemic therapy, n (%)

Feature	n = 38
First-line treatment
Temozolomide/capecitabine	35 (92.1)
CAPOX	1 (2.6)
Cisplatin/etoposide	1 (2.6)
Interferon alpha	1 (2.6)
First-line cycles
Median (IQR)	9 (6-22.75)
Duration of first-line treatment, days
Median (IQR)	331 (133.25-606)
Second-line treatment
Yes	14 (36.8)
No	24 (63.2)
Second-line regimen, n = 14
Capecitabine	4 (28.6)
CAPOX	3 (21.4)
TEMCAP	3 (21.4)
Cisplatin/etoposide	1 (7.1)
Dacarbazine (DTIC)	1 (7.1)
GEMOX	1 (7.1)
Temozolomide	1 (7.1)

IQR: Interquartile range; TEMCAP: Temozolomide and capecitabine regimen; CAPOX: capecitabine/oxaliplatin; GEMOX: gemcitabine/oxaliplatin.